Biosolution Co.,Ltd.
Financials
Valuation Metrics
Biosolution Co.,Ltd.'s Market Cap is ₩1566B. At end of 2025 it was ₩2051B. Ranked #960 of 2,436 in KR market (top 39%), #463 of 1,649 on KOSDAQ (top 28%), #111 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 47%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 156.58B KRW | KR#960/2,436 Sec#111/234 |
| Revenue | 15.82B KRW | KR#2,199/2,436 Sec#163/234 |
| Net Income | 654.9M KRW | KR#1,450/2,436 Sec#99/234 |
| Total Assets | 66.37B KRW | KR#2,021/2,436 Sec#171/234 |
| Net Assets | 41.94B KRW | KR#2,001/2,436 Sec#173/234 |
| Employees | 88 | KR#1,725/2,436 Sec#135/234 |
| Value | ||
| P/E | 239.09x | KR#1,478/2,436 Sec#102/234 |
| P/B | 3.73x | KR#2,181/2,436 Sec#177/234 |
| P/S | 9.90x | KR#2,266/2,436 Sec#161/234 |
| FCF Yield | -0.96% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 1.56% | KR#1,369/2,436 Sec#95/234 |
| ROA | 0.99% | KR#1,324/2,436 Sec#95/234 |
| Op. Margin | -26.94% | KR#2,167/2,436 Sec#149/234 |
| Revenue Growth | 19.87% | KR#644/2,436 Sec#62/234 |
| Financial Health | ||
| Debt Ratio | 158.23% | KR#1,298/2,436 Sec#148/234 |
| Total Debt | 18.22B KRW | KR#1,391/2,436 Sec#115/234 |
| FCF | -1.50B KRW | KR#1,310/2,436 Sec#102/234 |
| Cash | 11.15B KRW | KR#1,612/2,436 Sec#122/234 |
| Current Ratio | 0.81x | KR#2,025/2,436 Sec#193/234 |
| Performance | ||
| 1Y Return | -23.83% | KR#1,393/2,436 Sec#120/234 |
| 1M Return | 2.20% | KR#672/2,436 Sec#59/234 |
| From 52W High | -55.09% | KR#1,445/2,436 Sec#123/234 |
| 1Y MDD | -57.45% | KR#1,274/2,436 Sec#105/234 |
| Trading | ||
| Volume | 53,034 shares | KR#1,294/2,436 Sec#127/234 |
| Foreign Own. | 3.19% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 27 KRW | KR#1,481/2,436 Sec#103/234 |
| BPS | 1,625 KRW | KR#2,127/2,436 Sec#184/234 |
Company Info
Established in 2000 as a cell therapy developer, the company changed its name in 2016, listed on KOSDAQ in 2018, and established local subsidiaries in China and Australia during the current period. It operates businesses in cell therapies, human stem cell-derived materials, peptide cosmetic ingredients, human tissue models, and alternative testing services. Following the commercialization of autologous cell therapies, the company is developing allogeneic cell therapies to expand commercialization and versatility. It is also expanding cosmetic ingredients through market expansion via human tissue model certification and joint research. BIOSOLUTIONS is headquartered in Nowon-gu, Seoul.